GPT and hemophilia B: In another gene therapy study of an AAV5 vector in 54 patients with hemophilia B, participants received a transgene dose of 2.0 × 1013 GC/kg; glucocorticoid therapy was necessary in nine participants with elevated ALT levels and was administered over a range of 51–130 days (mean 79.8 days) [21].